arrow
A

Aykut Soyder

acıbadem mehmet ali aydınlar university
H指数:15
被引数:1,060

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a

原发灶区域性治疗在无内脏转移的乳腺癌骨转移患者中的应用:前瞻性、多中心真实世界数据,BOMETIN研究,方案MF14-1a

2025-10-040
OAAI
Biologically Informed Decision-Making for PMRT in pT3N0M0 Luminal Breast Cancers (Protocol MF22-02): International Multicenter Real-World Data

基于生物信息的术后放疗决策在pT3N0M0 Luminal型乳腺癌中的应用(方案MF22-02):国际多中心真实世界数据

2025-04-230
PRE
ASO Visual Abstract: Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in the NEOSENTITURK-trials MF18-02/18-03
2025-02-180
PRE
Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03
2024-12-022
PRE
Combined analysis of the MF18-02/MF18-03 NEOSENTITURK studies: ypN-positive disease does not necessitate axillary lymph node dissection in patients with breast cancer with a good response to neoadjuvant chemotherapy as long as radiotherapy is provided
CANCER
IF5.1
2024-10-300
OAAI
PMRT Decision with low prediction of genomic test score in pT3N0M0 luminal breast cancer: Protocol MF22-02: International multicenter realworld data
2024-05-020
PRE
Loco-regional Treatment in De Novo Bone Only Metastatic Breast Cancer; Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a
2024-05-020
PRE
Feasibility and oncological safety of targeted axillary dissection or sentinel lymph node biopsy in patients with clinically node-positive disease after neoadjuvant chemotherapy in the prospective MF-1803 NEOSENTITURK-study
2024-05-020
PRE
AXILLARY NODAL RECURRENCE IS RARE IN PATIENTS WITH NODE-POSITIVE BREAST CANCER UNDERGOING SLNB FOLLOWING NEOADJUVANT CHEMOTHERAPY : EARLY RESULTS OF THE NEOSENTITURK-TRIAL/MF-18-03
2023-03-010
PRE
Association of biochemical and clinical parameters with parathyroid adenoma weight. Turkish-Bulgarian endocrine and breast surgery study group, hyperparathyroidism registry study
2022-01-011
OAAI
The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study
2021-02-0254
PRE
Surgical Trends in Breast Cancer in Turkey: An Increase in Breast-Conserving Surgery
2020-11-0111
OAAI
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01
2018-05-17256
OAAI
The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post-hoc analyses of protocol MF07-01
2017-02-150
PRE
Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01)
2013-12-1521
PRE